Lyell Immunopharma, Inc. financial data

Symbol
LYEL on Nasdaq
Location
201 Haskins Way, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 859 % -47.6%
Debt-to-equity 24.3 % +65.1%
Return On Equity -85.6 % -157%
Return On Assets -68.9 % -137%
Operating Margin -594K % -42.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.2M shares -92.5%
Common Stock, Shares, Outstanding 14.8M shares -94.2%
Entity Public Float 306M USD -53.2%
Common Stock, Value, Issued 1K USD -96.2%
Weighted Average Number of Shares Outstanding, Basic 14.8M shares +15.8%
Weighted Average Number of Shares Outstanding, Diluted 14.8M shares +15.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 60K USD +11.1%
Research and Development Expense 34.9M USD -13.4%
General and Administrative Expense 50.1M USD -7.9%
Operating Income (Loss) -356M USD -57.8%
Nonoperating Income (Expense) 24.8M USD +60.9%
Net Income (Loss) Attributable to Parent -331M USD -57.6%
Earnings Per Share, Basic 0 USD/shares +87%
Earnings Per Share, Diluted 0 USD/shares +87%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 98.8M USD -25.9%
Marketable Securities, Current 178M USD -50.2%
Assets, Current 282M USD -43.5%
Property, Plant and Equipment, Net 39.1M USD -58%
Operating Lease, Right-of-Use Asset 21M USD -44.4%
Other Assets, Noncurrent 2.53M USD -40.3%
Assets 385M USD -41.1%
Accounts Payable, Current 3.38M USD -19.5%
Liabilities, Current 36.9M USD +19.5%
Operating Lease, Liability, Noncurrent 46.6M USD -12.6%
Other Liabilities, Noncurrent 3.03M USD -11.9%
Liabilities 86.5M USD -1.27%
Accumulated Other Comprehensive Income (Loss), Net of Tax 57K USD
Retained Earnings (Accumulated Deficit) -1.44B USD -29.9%
Stockholders' Equity Attributable to Parent 299M USD -47.2%
Liabilities and Equity 385M USD -41.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.7M USD -30.3%
Net Cash Provided by (Used in) Financing Activities 27K USD
Net Cash Provided by (Used in) Investing Activities 69.5M USD +216%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 14.8M shares -94.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.7M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 100M USD -24.9%
Deferred Tax Assets, Valuation Allowance 359M USD +44.7%
Deferred Tax Assets, Gross 366M USD +39.1%
Operating Lease, Liability 55.1M USD -8.49%
Payments to Acquire Property, Plant, and Equipment 246K USD +720%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -331M USD -58.9%
Lessee, Operating Lease, Liability, to be Paid 68.2M USD -12.5%
Property, Plant and Equipment, Gross 119M USD -23%
Operating Lease, Liability, Current 8.51M USD +23.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.3M USD +9.27%
Lessee, Operating Lease, Liability, to be Paid, Year One 13M USD +9.28%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 13.1M USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13M USD +3.47%
Deferred Tax Assets, Operating Loss Carryforwards 176M USD +32.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.66M USD +815%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.4M USD -19.6%
Additional Paid in Capital 1.74B USD +3.78%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.44M USD -31.5%
Deferred Tax Assets, Net of Valuation Allowance 6.92M USD -53.7%
Share-based Payment Arrangement, Expense 26.7M USD -26.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%